Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ipilimumab

View Patient Information
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.
Synonym:anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
ipilimumab biosimilar CS1002
MOAB CTLA-4
monoclonal antibody CTLA-4
US brand name:Yervoy
Abbreviation:MDX-CTLA-4
Code name:BMS-734016
IBI310
MDX-010
IND number:10200
NSC code:720801
Search NCI's Drug Dictionary